Evidence map›Paper›PMID 40137891›Full record

ArticleToxins2025

Cylindracin, a Fruiting Body-Specific Protein of

Yamato Kuratani, Akira Matsumoto, Ayako Shigenaga, Koji Miyahara, Keisuke Ekino, Noriaki Saigusa, Hiroto Ohta, Makoto Iwata, Shoji Ando

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yamato KurataniFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.ORCID 0009-0002-1670-243X
Akira MatsumotoFaculty of Medicine, Juntendo University, 1-1 Hiraka Gakuendai, Inzai 270-1606, Japan.
Ayako ShigenagaInstitute of Health and Sports Science & Medicine, Graduate School of Health and Sports Science, Juntendo University, 1-1 Hiraka Gakuendai, Inzai 270-1695, Japan.
Koji MiyaharaFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.
Keisuke EkinoFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.
Noriaki SaigusaFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.
Hiroto OhtaFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.
Makoto IwataIMB Co., Ltd., 1070-10 Hitotsugi, Asakura 838-0065, Japan.
Shoji AndoFaculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mushrooms are a valuable source of bioactive compounds to develop efficient, secure medicines and environmentally friendly agrochemicals. Cylindracin is a small cysteine-rich protein that is specifically expressed in the immature fruiting body of the edible mushroom

Indexed as

Caenorhabditis elegansDrosophila melanogasterFruiting Bodies, FungalOvipositionAnimalsFemaleLarvaMaleRecombinant ProteinsRecombinant Proteinsantifungal proteinbasidiomycetesCaenorhabditis elegansCyclocybe cylindraceacylindracinDrosophila melanogasterhost defense activity

Identifiers

PMID40137891
PMCPMC11946224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.